# **Product** Data Sheet

## MS8511

Cat. No.: HY-150510 CAS No.: 2866408-21-9 Molecular Formula:  $C_{28}H_{41}N_5O_3$  Molecular Weight: 495.66

Target: Histone Methyltransferase

Pathway: Epigenetics

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

/	NH		
<b>\</b>	O N N	J_0^	√N \

#### **BIOLOGICAL ACTIVITY**

Description

MS8511 is a selective G9a/GLP covalent irreversible inhibitor by targeting a cysteine residue at the substrate binding site, with IC $_{50}$  values of 100 nM (G9a) and 140 nM (GLP), and K $_{d}$  values of 44 nM (G9a) and 46 nM (GLP). MS8511 reduces the cellular H3K9me2 level and enhances antiproliferation activity. MS8511 can be used for the research of several types of cancers including brain, breast, ovarian, lung, bladder, melanoma, colorectal cancer, and other disease such as Alzheimer's disease (AD), sickle cell disease, Prader–Willi syndrome (PWS)<sup>[1]</sup>.

IC<sub>50</sub> & Target

G9a 100 nM (IC<sub>50</sub>) G9a

44 nM (Kd)

GLP 140 nM (IC<sub>50</sub>) GLP

46 nM (Kd)

In Vitro

MS8511 (Compound 8, 0-100  $\mu$ M, 10 min) selectively inhibits G9a and GLP against other PKMTs and PRMTs, with IC<sub>50</sub> values of 100 nM (G9a) and 140 nM (GLP)<sup>[1]</sup>.

MS8511 (50 min) prefers covalent modification for G9a over GLP, with K<sub>d</sub> values of 44 nM (G9a) and 46 nM (GLP)<sup>[1]</sup>.

MS8511 (0-5 µM, 24-72 h) effectively reduces the H3K9me2 mark in MDA-MB-231 and K562 cellssup>[1].

MS8511 (0.8-25  $\mu$ M, 3 days) inhibits the growth of MDA-MB-231 cells<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis<sup>[1]</sup>

Cell Line:	MDA-MB-231, K562 cells.
Concentration:	0.2, 1, 5 μΜ.
Incubation Time:	24, 48, 72 h.
Result:	Reduced the H3K9me2 mark in a concentration- and time-dependent manner.

#### Cell Viability Assay<sup>[1]</sup>

Cell Line:	MDA-MB-231 cells
Concentration:	0.8, 1.6, 3.1 6.3, 12.5, 25 μM.
Incubation Time:	3 days

Desuits. Inhibited the grounth of MDA MD 221 cells		
Result: Infinited the growth of MDA-MB-231 Cells.	Result:	Inhibited the growth of MDA-MB-231 cells.

### **REFERENCES**

[1]. Kwang-Su Park, et al. Discovery of the First-in-Class G9a/GLP Covalent Inhibitors. J Med Chem. 2022 Jun 28.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com